Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jun 4, 2019- Targeting CXCR4 May Impact Aggressive Metastatic Behavior of Cancer Cells, Which May be Related to a Poor PrognosisEisai today announced additional data from an ongoing Phase 1 trial exploring the investigational combination of eribulin and balixafortide, a CXCR4 antagonist, in patients with HER2-negative...
Jun 4, 2019Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Patrick Coyle as Vice President and Chief Financial Officer (CFO). In this role, Mr....
May 29, 2019Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Adriana Herrera as Senior Vice President, Americas Commercial Oncology. Herrera will...
-
May 28, 2019Data to be presented include:
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") today announced eight poster presentations on lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder,...
May 20, 2019Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group....
-
May 16, 2019- Data highlight continued progress on clinical trials for the LENVIMA plus KEYTRUDA combination across multiple tumor types, including endometrial carcinoma (EC), for which the combination was granted U.S. FDA Breakthrough Therapy Designation in July 2018
Eisai today announced the presentation of new data and analyses in one oral presentation, 11 posters at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4 in...
-
May 13, 2019
The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the investigational oral BACE (beta amyloid cleaving...
-
May 9, 2019-- Eisai presents key data from three retrospective real-world analyses at the 2019 American Academy of Neurology (AAN) Annual Meeting
Eisai Inc. presented the latest clinical results on FYCOMPA® (perampanel) CIII, at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, including analyses highlighting the...
May 2, 2019Dr. Harald Hampel hired as Vice President, Global Medical Affairs, Alzheimer's Disease;In its relentless pursuit to develop medications that will address the entire scope of Alzheimer's disease (AD), Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced...
-
Apr 30, 2019
Eisai Inc. and Purdue Pharma L.P. today announced that Eisai will buy out Purdue's rights to the worldwide collaboration for the development and commercialization of lemborexant, an...